Halozyme Therapeutics, Inc. (HALO): Price and Financial Metrics


Halozyme Therapeutics, Inc. (HALO): $44.82

0.49 (+1.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HALO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HALO POWR Grades


  • Quality is the dimension where HALO ranks best; there it ranks ahead of 81.51% of US stocks.
  • HALO's strongest trending metric is Quality; it's been moving up over the last 179 days.
  • HALO ranks lowest in Momentum; there it ranks in the 4th percentile.

HALO Stock Summary

  • The ratio of debt to operating expenses for Halozyme Therapeutics Inc is higher than it is for about 90.98% of US stocks.
  • HALO's price/sales ratio is 12.52; that's higher than the P/S ratio of 88.33% of US stocks.
  • With a year-over-year growth in debt of 120.7%, Halozyme Therapeutics Inc's debt growth rate surpasses 91.38% of about US stocks.
  • Stocks that are quantitatively similar to HALO, based on their financial statements, market capitalization, and price volatility, are GH, MODN, GWRE, PINS, and AYRO.
  • HALO's SEC filings can be seen here. And to visit Halozyme Therapeutics Inc's official web site, go to www.halozyme.com.

HALO Valuation Summary

  • In comparison to the median Healthcare stock, HALO's price/earnings ratio is 28.49% lower, now standing at 26.1.
  • HALO's price/sales ratio has moved down 125.2 over the prior 213 months.
  • Over the past 213 months, HALO's price/sales ratio has gone down 125.2.

Below are key valuation metrics over time for HALO.

Stock Date P/S P/B P/E EV/EBIT
HALO 2021-08-31 14.5 49.9 26.1 26.4
HALO 2021-08-30 14.5 49.9 26.1 26.4
HALO 2021-08-27 14.5 49.9 26.1 26.4
HALO 2021-08-26 13.9 47.9 25.1 25.4
HALO 2021-08-25 14.2 48.8 25.5 25.8
HALO 2021-08-24 14.0 48.1 25.2 25.5

HALO Growth Metrics

    Its 2 year revenue growth rate is now at -48.29%.
  • The year over year net cashflow from operations growth rate now stands at 238.15%.
  • Its 5 year price growth rate is now at 155.35%.
Over the past 15 months, HALO's revenue has gone up $243,754,000.

The table below shows HALO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 443.31 299.44 402.71
2021-09-30 463.01 267.844 409.104
2021-06-30 412.496 152.189 228.724
2021-03-31 331.262 118.594 163.083
2020-12-31 267.594 55.454 129.085
2020-09-30 199.556 -22.091 21.524

HALO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HALO has a Quality Grade of C, ranking ahead of 73.97% of graded US stocks.
  • HALO's asset turnover comes in at 0.493 -- ranking 84th of 682 Pharmaceutical Products stocks.
  • ARAV, XOMA, and MGNX are the stocks whose asset turnover ratios are most correlated with HALO.

The table below shows HALO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.493 0.814 0.250
2021-06-30 0.533 0.823 0.255
2021-03-31 0.510 0.832 0.224
2020-12-31 0.504 0.838 0.220
2020-09-30 0.378 0.831 0.053
2020-06-30 0.369 0.720 -0.037

HALO Price Target

For more insight on analysts targets of HALO, see our HALO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $52.82 Average Broker Recommendation 1.62 (Moderate Buy)

HALO Stock Price Chart Interactive Chart >

Price chart for HALO

HALO Price/Volume Stats

Current price $44.82 52-week high $46.62
Prev. close $44.33 52-week low $31.36
Day low $43.75 Volume 826,668
Day high $45.16 Avg. volume 946,940
50-day MA $40.81 Dividend yield N/A
200-day MA $38.32 Market Cap 6.18B

Halozyme Therapeutics, Inc. (HALO) Company Bio


Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. The company was founded in 1998 and is based in San Diego, California.


HALO Latest News Stream


Event/Time News Detail
Loading, please wait...

HALO Latest Social Stream


Loading social stream, please wait...

View Full HALO Social Stream

Latest HALO News From Around the Web

Below are the latest news stories about Halozyme Therapeutics Inc that investors may wish to consider to help them evaluate HALO as an investment opportunity.

Halozyme''s Q4 Earnings Beat Consensus Despite Lower Product Sales Hit Topline Growth

Halozyme Therapeutics Inc (NASDAQ: HALO ) reported Q4 revenue of $102 million compared to $121.7 million a year ago, beating the consensus of $100.32 million. The decrease was primarily driven by a decline in revenue under collaboration agreement and product sales, partially offset by an increase in royalty revenue attributable to subcutaneous Darzalex (daratumumab). Revenue for Q4 included $62.6 million in royalties. Adjusted EPS of $0.42 beat Full story available on Benzinga.com

Benzinga | February 23, 2022

Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues

Halozyme (HALO) fourth-quarter earnings and sales beat estimates. The company expects royalty revenues to grow by approximately 50% in 2022.

Yahoo | February 23, 2022

Halozyme Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation

No summary available.

Seeking Alpha | February 22, 2022

Halozyme Therapeutics, Inc.''s (HALO) CEO Helen Torley On Q4 2021 Results - Earnings Call Transcript

No summary available.

Seeking Alpha | February 22, 2022

Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01, revenue of $102M beats by $2.31M

Halozyme Therapeutics press release (HALO): Q4 Non-GAAP EPS of $0.42 beats by $0.01.Revenue of $102M (-16.2% Y/Y) beats by $2.31M.2022 Revenue Guidance of $530 to $560

Seeking Alpha | February 22, 2022

Read More 'HALO' Stories Here

HALO Price Returns

1-mo 2.96%
3-mo 32.84%
6-mo N/A
1-year 6.87%
3-year 190.85%
5-year 255.71%
YTD 11.46%
2021 -5.85%
2020 140.89%
2019 21.19%
2018 -27.79%
2017 105.06%

Continue Researching HALO

Want to see what other sources are saying about Halozyme Therapeutics Inc's financials and stock price? Try the links below:

Halozyme Therapeutics Inc (HALO) Stock Price | Nasdaq
Halozyme Therapeutics Inc (HALO) Stock Quote, History and News - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9562 seconds.